Tirschwell & Loewy Inc. Purchased $220,000 in Pfizer Inc. (PFE) Shares

Tirschwell & Loewy Inc. Purchased $220,000 in Pfizer Inc. (PFE) Shares

Tirschwell & Loewy Inc. bought a new stake in shares of Pfizer Inc. (NYSE:PFE) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 4,998 shares of the biopharmaceutical company’s stock, valued at approximately $220,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Fort L.P. purchased a new stake in shares of Pfizer in the second quarter worth $121,000. Selective Wealth Management purchased a new position in Pfizer during the third quarter valued at $155,000. Smart Portfolios LLC grew its stake in Pfizer by 43.9% during the second quarter. Smart Portfolios LLC now owns 3,935 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 1,200 shares in the last quarter. Moody Aldrich Partners LLC purchased a new position in Pfizer during the second quarter valued at $154,045,000. Finally, Sterling Global Strategies LLC purchased a new position in Pfizer during the third quarter valued at $201,000. 70.61% of the stock is owned by hedge funds and other institutional investors.

Several research firms recently weighed in on PFE. Barclays set a $40.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Friday, October 19th. Credit Suisse Group set a $45.00 target price on shares of Pfizer and gave the company a “hold” rating in a research note on Thursday, December 13th. JPMorgan Chase & Co. cut shares of Pfizer from an “overweight” rating to a “neutral” rating and set a $46.00 target price for the company. in a research note on Tuesday, December 11th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $53.00 target price on shares of Pfizer in a research note on Tuesday, December 11th. Finally, Wolfe Research began coverage on shares of Pfizer in a research note on Tuesday, October 23rd. They set a “market perform” rating for the company. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $44.68.

PFE stock traded up $0.04 during trading on Tuesday, hitting $41.72. 4,056,043 shares of the company’s stock traded hands, compared to its average volume of 26,838,350. Pfizer Inc. has a 52 week low of $34.03 and a 52 week high of $46.47. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $248.12 billion, a P/E ratio of 13.91, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 29th. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.01. Pfizer had a net margin of 20.79% and a return on equity of 25.38%. The business had revenue of $13.98 billion during the quarter, compared to analyst estimates of $13.92 billion. During the same quarter last year, the business earned $0.62 earnings per share. Pfizer’s quarterly revenue was up 2.0% compared to the same quarter last year. As a group, analysts anticipate that Pfizer Inc. will post 2.86 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 1st. Shareholders of record on Friday, February 1st will be given a dividend of $0.36 per share. The ex-dividend date of this dividend is Thursday, January 31st. This represents a $1.44 annualized dividend and a yield of 3.45%. This is a positive change from Pfizer’s previous quarterly dividend of $0.34. Pfizer’s dividend payout ratio (DPR) is 48.00%.

Pfizer announced that its board has initiated a stock buyback program on Friday, December 14th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to buy up to 3.8% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s management believes its shares are undervalued.

In other Pfizer news, EVP Douglas M. Lankler sold 5,000 shares of the stock in a transaction on Friday, February 1st. The shares were sold at an average price of $42.75, for a total transaction of $213,750.00. Following the completion of the transaction, the executive vice president now owns 83,592 shares in the company, valued at $3,573,558. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Douglas M. Lankler sold 38,800 shares of the stock in a transaction on Wednesday, January 30th. The shares were sold at an average price of $41.19, for a total transaction of $1,598,172.00. Following the transaction, the executive vice president now owns 83,592 shares of the company’s stock, valued at approximately $3,443,154.48. The disclosure for this sale can be found here. 0.06% of the stock is owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Further Reading: Does the discount rate affect the economy?

Related posts

Leave a Comment